MODIFICATION
66 -- Questions and Answers relating to Joint Biological Agent Identification and Diagnostic Systems (JBAIDS) Synopsis
- Notice Date
- 3/28/2002
- Notice Type
- Modification
- Contracting Office
- US Army Space and Missile Defense Command, Deputy Commander, ATTN SMDC-CM-AP, P.O. Box 1500, Huntsville, AL 35807-3801
- ZIP Code
- 35807-3801
- Solicitation Number
- DASG60-02-R-0008
- Response Due
- 3/28/2002
- Archive Date
- 4/27/2002
- Point of Contact
- Warren Potter, 301-619-2383
- E-Mail Address
-
Email your questions to US Army Space and Missile Defense Command, Deputy Commander
(PotterW@smdc.army.mil)
- Small Business Set-Aside
- N/A
- Description
- NA The following questions and answers are provided for information only. They are not intended to change any of the requirements for offorer provided information in response to Phase 1 of subject Synopsis. Therefore, the Phase 1 Offeror Response date remai ns March 28, 2002. Question 1: As part of the requirement for the consideration of the subject solicitation, is the government providing antibody reagents against the biological agents? Answer 1: The Government will provide reagent source material to the successful JBAIDS o fferor. If the offeror is using protein antibody technology to identify the Government's JBAIDS' BW agents of interest, antibody source materials will be provided. It is the contractor's responsibility to take this material and incorporate this material into the JBAIDS' reagent kits' design effort. The design and performance of the reagent kit for each agent of interest will be demonstrated in the fly off phase of the program, during the development program, and in production. Please note JBAIDS' system performance in the areas of specificity and sensitivity remains the contractor's responsibility. Also, a contractor has the latitude to not to use the DoD CRP antibody material, if the contractor believes better antibodies are available from other source s. However, no JBAIDS' schedule relief will be provided during the fly off, development phase, or in production for lack of antibody source material. Question 2: Is it required of the offeror to have sourced materials and reagents in a development phase for submission of Phase 1? Answer 2: There is no requirement for the offeror to have antibody source material in development for submission of JBAIDS' Phase I source selection information. Question 3: Is the CRP supporting the JBAIDS project with the spe cific reagents necessary for production? Answer 3: The CRP program will provide specific source material only. Again, the contractor has the latitude not to use the DoD CRP antibody material if the contractor believes better antibodies are available from other sources. However, no JBAIDS' schedule relief will be provided during the fly off, development phase, or in production for lack of antibody source material. Question 4: Is the information submitted in proposals viewed as confidential or is it access ible for general consumption? Answer 4: Before award, your proposal is not shared with anyone, except those approved to evaluate it for purposes of award. If you receive an award, your proposal then would be subject to release under the Freedom of Inform ation Act, but only if it is specifically requested by someone, and only then if does not contain ?proprietary information.? If you feel your proposal contains things you do not want revealed under the Freedom of Information Act, marking it ?proprietary? would be an effective way of signaling your concerns to the government contracting staff, who, regardless of a ?proprietary? marking, would notify and consult you whenever anyone requested a copy of your proposal. Question 5: Can the proposal be submitted on March 28, 2002 or should it be submitted before March 28, 2002? Answer 5: The offeror?s response to Phase 1 of subject synopsis must be received either by conventional mail/delivery services or electronically to the email address provided in the synop sis by (meaning on or before) March 28, 2002. Question 6: In Phase I, to support the screening criterion 1 is it necessary to provide complete list of data to demonstrate that ?prospective offeror has available for Government inspection Supporting Test Da ta for Performance Claims? or it will be satisfactory to provide the Performance Claims only? Answer 6: Subject synopsis provides that ?The initial Government screening process for JBAIDS will require perspective contractors to adequately describe and prov ide documentation as to how they will be able to produce and deliver within a period of 7 months the initial systems. Your description and d ocumentation must demonstrate the prospective offeror?s ability to meet all of the initial screening criteria?. The description and documentation chosen by your company to demonstrate your ability to meet the criteria that ?Prospective offeror has possess ion of a System Science/Methodology to Identify BW Agent/Toxin Agents/Pathogens and has available for Government inspection Supporting Test Data for Performance Claims? may (in your Phase 1 submission) include a listing or general description of test data that is available for Government inspection. The actual test data is not required as a part of the Phase 1 submission. Question 7: How many test kits are envisioned to be delivered 7-8 month ACA? Answer 7: That information will be provided as a part of the Phase 3 purchase order package. Question 8: What is the envisioned duration of Block I project? Answer 8: FY02 to FY07.
- Place of Performance
- Address: US Army Space and Missile Defense Command, Deputy Commander ATTN SMDC-CM-AP, P.O. Box 1500 Huntsville AL
- Zip Code: 35807-3801
- Country: US
- Zip Code: 35807-3801
- Record
- SN00049857-W 20020330/020328213417 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |